Drugs / ELTRAPULDENCEL-T
ELTRAPULDENCEL-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01828762 | Dec 2012 → Dec 2013 | hepatocellular carcinoma | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELTRAPULDENCEL-T | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544925 ↗ |
| Known as | DC-TC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01828762 ↗ |
| Known as | Eltrapuldencel | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544925 ↗ |
| Known as | NBS-20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544925 ↗ |
| Modality | Cell therapy | “subcutaneous injections of autologous dendritic cells incubated with irradiated autologous tumor stem cells and suspended in GM-CSF” NCT01828762 ↗ |
| Route | Subcutaneous | “subcutaneous injections of autologous dendritic cells incubated with irradiated autologous tumor stem cells and suspended in GM-CSF” NCT01828762 ↗ |